Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation

International Journal of Biological Macromolecules

Volumn 67, Issue , 2014, Pages 418-425

  Bhavna, ^a   Md, Shadab ^b   Ali, Mushir ^b   Ali, Rashid ^c   Bhatnagar, Aseem ^c   Baboota, Sanjula ^b   Ali, Javed ^b  

^a DIT UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Intranasal delivery; Ionic crosslinking; Nanosuspension

Indexed keywords

CHITOSAN; DONEPEZIL; NANOPARTICLE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NANOMATERIAL; PIPERIDINE DERIVATIVE; SUSPENSION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANNULA; CONTROLLED STUDY; CROSS LINKING; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORGAN WEIGHT; RAT; SUSPENSION; ADMINISTRATION AND DOSAGE; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; DRUG EFFECTS; EVALUATION STUDY; INTRANASAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DRUG DELIVERY SYSTEMS; IN VITRO TECHNIQUES; INDANS; NANOSTRUCTURES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUSPENSIONS;

EID: 84898997453     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2014.03.022     Document Type: Article

References (37)

1. Mayeux R., Sano.F M. N. Engl. J. Med. 1999, 341:1670-1679.
2. Butterfield D.A. Brain. Res. 2004, 1000:1-7.
3. Rho J.P., Lipson L.G. Formulary 1997, 32:677-678.
4. Rogers S.L., Doody R.S., Mohs R.C., et al. Arch. Intern. Med. 1998, 158:1021-1031.
5. Yamanishi Y. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors. Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases 1990, Plenum Press, New York, NY.
6. Fazil M., Md S., Haque S., et al. Eur. J. Pharm. Sci. 2012, 47:6-15.
7. Bartus R.T., Dean R.L., Beer B., et al. Science (Wash DC) 1982, 217:408-417.
8. Costantino H.R., Illum L., Brandt G., et al. Int. J. Pharm. 2007, 337:1-24.
9. Wang Y., Aun R., Tse F.L. Biopharm. Drug Dispos. 1998, 19:571-575.
10. Chow H.S., Chen Z., Matsuura G.T. J. Pharm. Sci. 1999, 88:754-758.
11. Zhang Q.Z., Jiang X.G., Wu C.H. Acta Pharmacol. Sin. 2004, 25:522-527.
12. Westin U.E., Bostrom E., Grasjo J., et al. Pharm. Res. 2006, 23:565-572.
13. Westin U., Piras E., Jansson BF B., et al. Eur. J. Pharm. Sci. 2005, 24:565-573.
14. Dahlin M., Bjork E. Int. J. Pharm. 2001, 212:267-274.
15. Berg M.P., Merkus P., Romeijn S.G., et al. J. Drug Target. 2003, 11:325-331.
16. Berg M.P., Merkus P., Romeijn S.G., et al. Pharm. Res. 2004, 21:799-802.
17. Sakane T., Akizuki M., Yamashita S., et al. Chem. Pharm. Bull. (Tokyo) 1991, 39:2456-2458.
18. Sakane T., Akizuki M., Yamashita S., et al. J. Pharm. Pharmacol. 1994, 46:378-389.
19. Christodoulou C., Melville P., Scherl W.F., et al. J. Neurol. Sci. 2006, 245-250.
20. Bhavna S., Md M., Ali M., et al. Drug. Dev. Ind. Pharm. 2013, 10.3109/03639045.2012.758130.
21. Calvo P., Remunan-Lopez C., Vila-Jata J.L., et al. Pharm. Res. 1997, 14:1431-1436.
22. Bhavna V., Sharma M., Ali M., et al. Ind. J. Pharm. Sci 2007, 712-723.
23. Zheng J.P., Luan L., Wang H.Y., Xi L.F., Yao K.D. Appl. Clay Sci. 2007, 36:297-301.
24. Ali J., Ali M., Baboota S., et al. Curr. Nanosci. 2010, 6(3):320-323.
25. Pappa H., Farru R., Vilanova P.O., et al. J. Pharm. Biomed. Anal. 2002, 27:177-182.
26. Tsai M.L., Chen R.H., Bai S.W., et al. Carbohydr. Polym. 2011, 84:756-761.
27. Agnihotri S.A., Mallikarjuna N.N., Aminabhavi T.M. J. Control. Release 2004, 100:5-28.
28. Wu Y., Yang W., Wang C C., et al. Int. J. Pharm. 2005, 295:235-245.
29. Barakat N.S., Omar S.A., Ahmed A.A.E. J. Pharm. Pharmacol. 2005, 58:63-72.
30. Cornford E.M., Cornford M.E. Lancet. Neurol. 2002, 1:306-315.
31. Begley D.J. J. Pharm. Pharmacol. 1996, 48:136-146.
32. Mathison S., Nagilla R., Kompella U.B. J. Drug Target. 1998, 5:415-441.
33. Wohlfart S., Khalansky A.S., Gelperina S., Begley D., Kreuter J. J. Control. Release 2011, 154:103-107.
34. Wohlfart S., Gelperina S., Kreuter J. J. Control. Release 2012, 161:264-273.
35. Gabathuler R. Neurobiol. Dis. 2010, 37:48-57.
36. Mistry A., Stolnik S., Illum L. Int. J. Pharm. 2009, 379:146-157.
37. Md S., Khan R.A., Mustafa G., Chuttani K., Baboota S., Sahni J.K., Ali J. Eur. J. Pharm. Sci. 2013, 48:393-405.